
1 **Association between Prolonged Intermittent Renal Replacement Therapy**
2 **and All-Cause Mortality in COVID-19 Patients Undergoing Invasive**
3 **Mechanical Ventilation: a Retrospective Cohort Study**

4 Yi Yang*, Jia Shi*, Shuwang Ge*, Shuiming Guo, Xue Xing, Yanan Wang, Anying Cheng,
5 Qingquan Liu, Junhua Li, Yong Ning, Fan He# and Gang Xu#

6

7 Department of Nephrology, Tongji Hospital Affiliated to Tongji Medical College,
8 Huazhong University of Science and Technology, Wuhan, China

9

10 Short title: PIRRT in COVID-19 patients

11

12 *These authors contributed equally to this work.

13 #Correspondence Author:

14 Fan He and Gang Xu

15 Department of Nephrology

16 Tongji Hospital Affiliated with Tongji Medical College, Huazhong University of Science
17 and Technology

18 1095 Jie Fang Avenue

19 Wuhan, Hubei 430030, China

20 Tel: +86-027-83662682 and +86-027-69378405

21 Email: fhe@tjh.tjmu.edu.cn and xugang@tjh.tjmu.edu.cn.

22

23 Number of Tables: 3

24 Number of Figures: 1

25 Word count: 2497

26 **Keywords** prolonged intermittent renal replacement therapy · COVID-19 · invasive
27 mechanical ventilation · mortality

28 **Abstract**

29 **Background:** For the coronavirus disease 2019 (COVID-19), critically ill patients had a
30 high mortality rate. We aimed to assess the association between prolonged intermittent
31 renal replacement therapy (PIRRT) and mortality in patients with COVID-19 undergoing
32 invasive mechanical ventilation. **Methods:** In this retrospective cohort study, we included
33 all patients with COVID-19 undergoing invasive mechanical ventilation from February
34 12nd to March 2nd, 2020. All patients were followed until death or March 28th, and all
35 survivors were followed for at least 30 days. **Results:** For 36 hospitalized COVID-19
36 patients with invasive mechanical ventilation, the mean age was 69.4 (± 10.8) years, and
37 30 patients (83.3%) were men. Twenty-two (61.1%) patients received PIRRT (PIRRT
38 group) and 14 cases (38.9%) were managed with conventional strategy (non-PIRRT
39 group). There were no differences in age, sex, comorbidities, complications, treatments
40 and most of the laboratory findings. During median follow-up period of 9.5
41 (interquartile range 4.3-33.5) days, 13 of 22 (59.1%) patients in the PIRRT group and 11
42 of 14 (78.6%) patients in the non-PIRRT group died. Kaplan–Meier analysis
43 demonstrated prolonged survival in patients in the PIRRT group compared with that in
44 the non-PIRRT group (P = 0.042). The association between PIRRT and a reduced risk of
45 mortality remained significant in three different models, with adjusted hazard ratios
46 varying from 0.332 to 0.398. Higher levels of IL-2 receptor, TNF- α , procalcitonin,
47 prothrombin time, and NT-proBNP were significantly associated with an increased risk
48 of mortality in patients with PIRRT. **Conclusion:** PIRRT may be beneficial for the
49 treatment of COVID-19 patients with invasive mechanical ventilation. Further
50 prospective multicenter studies with larger sample sizes are required.

51

52 **Introduction**

53 An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
54 infection, officially named Coronavirus Disease 2019 (COVID-19) occurred (1). In Wuhan,
55 the fatality rate of COVID-19 was 5.1% (2538/50006). Of note, critically ill patients with
56 COVID-19 have a high mortality rate. In a study of 52 critically ill patients in Wuhan, 32

57 (61.5%) patients had died after 28 days, and the mortality rate was 81.1% (30/37) in
58 patients requiring mechanical ventilation (2). Accumulated evidence has strongly
59 demonstrated that systemic inflammatory response, acute kidney injury (AKI) and fluid
60 overload (FO) were associated with high mortality in severe sepsis (3-5). In critically ill
61 patients with COVID-19, an overwhelming inflammatory response involving C-reactive
62 protein (CRP), interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor α (TNF- α) was
63 observed (6-9), which is similar to that observed in patients suffering from SARS-CoV
64 (10) and Middle East respiratory syndrome (MERS)-CoV (11).

65 Renal replacement therapy (RRT) is a great help in treating critically ill patients not
66 only to control electrolyte and acid-base imbalances but also to remove inflammatory
67 mediators and improve oxygenation during fluid overload (12-14). RRT has been
68 applied to critically ill patients, including patients with SARS-CoV, MERS-CoV and other
69 viral infectious diseases such as Ebola virus disease (13, 15). However, the benefits of
70 RRT are still no consistent conclusion in critically ill patients (16). RRT significantly
71 reduced the level of IL-6 and decreased the hospital mortality rate in pediatric severe
72 sepsis, especially in patients with acute respiratory distress syndrome (ARDS) (17). In
73 addition, a meta-analysis revealed that patients who received RRT had significantly
74 lower mortality compared to conventional therapy (18). However, RRT was associated
75 with increased mortality in patients with MERS-CoV (15). The relationship between RRT
76 and patient outcome varied in patients with different disease and was affected by the
77 modalities, use of anticoagulation, vascular access management, and the timing of the
78 initiation and intensity of RRT (16, 19, 20).

79 Prolonged intermittent renal replacement therapy (PIRRT), as a cost-effective
80 alternative, has been used in the intensive care unit (ICU) (21, 22). To date, no specific
81 treatment has been confirmed to be effective for COVID-19, and supportive treatment
82 remains essential. In this retrospective cohort study, we aimed to explore the association
83 between PIRRT and all-cause mortality in patients with COVID-19 undergoing invasive
84 mechanical ventilation.

85

86 **Materials and Methods**

87 *Study Design and Participants*

88 In this retrospective cohort study, we included all patients with COVID-19
89 undergoing invasive mechanical ventilation at the Optical Valley Branch of Tongji
90 Hospital, Wuhan, from February 12nd to March 2nd. We divided the study participants
91 into two groups according to the use of PIRRT treatment (PIRRT group and non-PIRRT
92 group).

93

94 *Inclusion and Exclusion Criteria*

95 All included patients met the criteria for the diagnosis of COVID-19 according to the
96 New Coronavirus Pneumonia Prevention and Control Program (5th edition, in Chinese)
97 published by the National Health Commission of China (23). Invasive mechanical
98 ventilation was defined as mechanical ventilation through an endotracheal tube or
99 tracheostomy. There were no exclusion criteria.

100

101 *Procedures*

102 The baseline data at the beginning of invasive mechanical ventilation for each
103 patient were collected and recorded at the start of invasive mechanical ventilation,
104 including age, sex, comorbidities, complications, laboratory data, and treatments. All
105 information was obtained and managed through established data collection forms. Two
106 researchers independently reviewed and collected the data. AKI was defined as a 50%
107 increase in serum creatinine within 7 days or a 0.3 mg/dL increase within 48 hours
108 according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria (24).

109

110 *PIRRT Procedures*

111 We performed PIRRT using commercially available pump-driven machines
112 (PrismaFlex, Gambro, Sweden; or multiFiltrate, Fresenius, Germany) and filters (M150,
113 Gambro; Oxiris, Baxter; or AV1000s, Fresenius). For the patients with AKI,
114 hemofiltration plus hemodialysis was performed. The blood flow rate was set at 2.5-4

115 mL/kg/min, and the clearance rate was set at 35-70 mL/kg/hr. The filter circuit was
116 prewashed with saline containing 5,000-6,250 IU/L heparin. Vascular access was
117 obtained with 13.5 F central venous catheters (Covidien, MA, USA) in the femoral vein.
118 9.1% (2/22) of patients received continuous hemodialysis. And 90.9% (20/22) of
119 patients received intermittent hemodialysis, 8 hours a day, once a day or every other day.
120 PIRRT modalities were venovenous hemodiafiltration in 22.7% (5/22) of patients and
121 venovenous hemofiltration in 77.3% (17/22) of patients.

122 The indications for PIRRT was: 1) Nonobstructive oliguria (urine output < 200
123 mL/12h) or anuria, or sepsis complicated by AKI; 2) Hyperkalemia (K^+ > 6.5 mmol/L); 3)
124 Acidemia (PH < 7.1); 4) Clinically significant organ edema (especially pulmonary edema);
125 5) Uremic complications (pericarditis/encephalopathy/neuropathy/myopathy); 6)
126 Azotaemia (urea > 30 mmol/L); 7) (optional) increased inflammatory cytokines (anyone
127 of IL-1 β , IL-2 receptor, IL-6, IL-8, or TNF- α \geq 5 times of upper limit of normal range).

128

129 *Outcomes*

130 We followed up all patients through electronic hospital medical records. The
131 primary outcome was death. All patients were followed until death or March 28th, and all
132 survivors were followed for at least 30 days. There was no loss to follow-up for patients.

133

134 *Statistical Analyses*

135 Numerical data are presented as the means and standard deviation (SD) or medians
136 [interquartile range (IQR)] and were analyzed using Student's t-test or the
137 Mann-Whitney U test depending on the data distribution. Categorical variables were
138 displayed as frequencies and percentages and were analyzed using Fisher's exact test.
139 Paired t test or Wilcoxon matched-pairs signed rank test was used to evaluate
140 differences of variables between before and after PIRRT. The Kaplan-Meier method was
141 used to estimate survival, and the log-rank test was used to evaluate differences between
142 the two groups. Univariate and multivariate Cox proportional hazards regression
143 analyses were performed for all-cause mortality. SPSS 23.0 (IBM Corporation, Armonk,

144 NY) statistical software was used for statistical analysis. GraphPad Prism 6 (GraphPad
145 Software, USA) was used for statistical analysis and visualization. A P-value of 0.05 or
146 less was considered significant.

147

148 **Results**

149 *Description of the Cohort*

150 In total, 36 COVID-19 patients subjected to invasive mechanical ventilation were
151 enrolled in the study. Table 1 shows the baseline characteristics of the cohort patients.
152 There were 30 men (83.3%) and 6 women (16.7%) ranging in age from 44 to 86 years.
153 30 patients (83.3%) have at least one comorbidity, and the common comorbidity factors
154 in COVID-19 patients with invasive mechanical ventilation were hypertension (n = 14,
155 38.9%) and cardiac disease (n = 12, 33.3%).

156 We divided the study participants into two groups according to PIRRT treatment.
157 Twenty-two patients received PIRRT (PIRRT group) while 14 patients did not
158 (non-PIRRT group). There was no difference between the two groups in baseline
159 characteristics including age, sex, acute physiology and chronic health evaluation
160 (APACHE) II scores, sepsis-related organ failure assessment (SOFA) scores,
161 comorbidities, complications, treatments or most laboratory findings, except for
162 patients who received PIRRT with higher levels of aspartate aminotransferase (P =
163 0.034) and serum creatinine (P = 0.017).

164 The indications for PIRRT (n = 22) were as follows: (1) AKI at stage 3 (serum
165 creatinine increase ≥ 3 times baseline with 7 days) with/without hyperkalemia or
166 pulmonary edema: n = 4; (2) hyperkalemia: n = 1; (3) acidemia: n = 1; (4) pulmonary
167 edema: n = 1; (5) (optional) increased inflammatory cytokines (anyone of IL-1 β , IL-2
168 receptor, IL-6, IL-8, or TNF- $\alpha \geq 5$ times of upper limit of normal range): n = 15. There
169 was no definite indication of PIRRT for patients in non-PIRRT group. Our evaluation of
170 dialysis indications was consistent in all patients, except for inflammatory cytokines.

171 Furthermore, in the PIRRT group, IL-6 showed a significant difference before versus
172 after PIRRT (before vs. after PIRRT: median 221.35, IQR 111.23-427.40, vs. median

173 48.53, IQR 12.93-119.23, pg/mL, P = 0.001).

174

175 *Association between PIRRT and All-Cause Mortality in COVID-19 Patients Undergoing*
176 *Invasive Mechanical Ventilation*

177 All survivors were followed for at least 30 days. During the median follow-up period
178 of 9.5 (IQR 4.3-33.5) days, 13 of 22 (59.1%) patients in the PIRRT group and 11 of 14
179 (78.6%) patients in the non-PIRRT group died. Kaplan–Meier analysis indicated that the
180 patients in the PIRRT group had prolonged survival compared to those in the non-PIRRT
181 group (P = 0.04) (shown in Fig. 1).

182 In the Cox regression analysis, three different models were used to analyze the
183 adjusted hazard ratio for PIRRT treatment. Consistently, the association between PIRRT
184 treatment and a reduced risk of mortality remained significant and the adjusted hazard
185 ratio (aHRs) of PIRRT treatment fluctuated between 0.332 and 0.398 (Table 2).

186

187 *Risk Factors Associated with All-Cause Mortality for COVID-19 Patients Undergoing*
188 *Invasive Mechanical Ventilation with PIRRT Treatment*

189 We further conducted univariate Cox proportional hazard regression analyses of
190 all-cause mortality of COVID-19 patients undergoing invasive mechanical ventilation
191 with PIRRT. We found that higher levels of IL-2 receptor, TNF- α , procalcitonin,
192 prothrombin time, and NT-proBNP were significantly associated with an increased risk
193 of all-cause mortality (Table 3).

194

195 **Discussion**

196 To the best of our knowledge, this study is the first cohort study to estimate the
197 association between PIRRT treatment and the mortality of COVID-19 patients subjected
198 to invasive mechanical ventilation. We included 36 COVID-19 patients subjected to
199 invasive mechanical ventilation, of whom 22 patients received PIRRT. During the
200 follow-up, 59.1% of patients in the PIRRT group, and 78.6% of patients in the non-PIRRT
201 group died. PIRRT was independently associated with prolonged survival and a lower

202 risk of mortality in COVID-19 patients requiring invasive mechanical ventilation.

203 Excessive inflammation characterized by the uncontrolled release of
204 pro-inflammatory cytokines into circulation is the main cause of death from sepsis (25,
205 26), and infection with influenza virus (27), Ebola virus (28), MERS-CoV (29), and
206 SARS-CoV (30). In our study, we found that the cytokine storm might play a crucial role
207 in critical COVID-19 patients. The mean/median levels of inflammatory markers,
208 including IL-1 β , IL-2 receptor, IL-6, IL-8, and IL-10, white blood cell count, neutrophil
209 count, hCRP, procalcitonin, and ferritin were higher than normal. And in our study,
210 univariate Cox proportional hazard regression analysis showed increased IL-6
211 [HR=1.004, 95% CI (1.001-1.007)] and TNF- α [HR=1.040, 95% CI (1.007-1.073)] were
212 both associated with increased risk of mortality of all patients with invasive mechanical
213 ventilation. In patients undergoing PIRRT, IL-6 showed significant difference before
214 versus after PIRRT: before vs. after PIRRT: 221.35 (IQR 111.23-427.40) vs. 48.53 (IQR
215 12.93-119.23), P=0.001.

216 Cytokine storms may be caused by the following aspects. First, SARS-CoV-2 infects
217 patients by binding human angiotensin (Ang)-converting enzyme 2 (ACE2) (31, 32),
218 which is widely expressed in multiple organs throughout the body (33). SARS-CoV-2
219 might lead to multisystem inflammation through the ACE/Ang II/AT1R pathway and the
220 ACE2/Ang (1-7)/Mas receptor pathway (34, 35). Second, it was reported that
221 antibody-dependent enhancement (ADE) of SARS-CoV-2 due to prior exposure to other
222 coronaviruses might also be involved in COVID-19 (36). ADE can elicit sustained
223 inflammation, lymphopenia, and/or cytokine storm, which is a possible explanation for
224 the geographic limitation of severe cases. Third, combined infections may lead to a more
225 severe systemic inflammatory response. Indeed, in our study, some patients had
226 infections in other organs (e.g. urinary tract and blood) caused by other pathogens (e.g.,
227 influenza virus and fungi). Fourth, shock, hypoxemia and coagulation pathway
228 abnormalities in critical patients could aggravate the systemic inflammatory response,
229 which lead to a vicious cycle that is life-threatening (37, 38).

230 In our study, PIRRT was associated with prolonged survival in COVID-19 patients

231 with invasive mechanical ventilation. The primary goal of RRT is to compensate for the
232 loss of renal function and associated sequelae, including uremic toxicity, electrolyte
233 disturbances, metabolic acidosis, and volume overload (22, 39). In addition, RRT can
234 also remove cytokines from the bloodstream. Emerging evidence has shown that RRT
235 was associated with significantly lower mortality in patients with severe sepsis (17, 18,
236 40). Besides, in patients with acute respiratory distress syndrome, RRT could remove
237 inflammatory mediators, modulate immune function, and regulate oxygenation, thus
238 improving patient prognosis (41-43). PIRRT is a widely used blood purification therapy,
239 that achieves a high solute clearance rate through diffusion and convection (44). PIRRT
240 has shown to encompass the benefits of both continuous RRT in terms of hemodynamic
241 stability and intermittent hemodialysis in terms of cost-efficiency in the intensive care
242 unit (22, 45).

243 However, it is controversial whether PIRRT is beneficial in viral pneumonia. RRT
244 was reported to have a positive effect on the treatment of adenovirus pneumonia (46).
245 Other studies revealed that PIRRT was a risk factor for mortality in patients with
246 MERS-CoV (15, 47). Yang et al also found that the proportion of nonsurvivors subjected
247 to RRT was higher among patients with COVID-19 (48). In our study, PIRRT was
248 associated with a reduced risk of mortality in COVID-19 patients requiring invasive
249 mechanical ventilation after adjusting for confounding factors. COVID-19 is a novel
250 infectious disease caused by a novel coronavirus, and the underlying pathophysiological
251 process associated with organ involvement is still unclear. In addition, the population
252 studied in our cohort was different from Yang et al., who focused on all critically ill
253 patients, while we focused on patients who received invasive mechanical ventilation.
254 Further research is needed to improve patient treatment and prognosis.

255 There were some limitations to our study. First, it is retrospective in design, and a
256 prospective double-blind randomized controlled study is warranted in the future.
257 Second, the sample size of this study was not large enough. Third, as it
258 is just a single-center study, multicenter studies are needed for further confirmation.

259 In summary, we demonstrated that PIRRT could improve COVID-19 patient survival

260 and might be an independent protective factor for COVID-19 patient survival, and might
261 be an independent protective factor for COVID-19 patients with invasive mechanical
262 ventilation. Further prospective multicenter studies with larger sample sizes are
263 required.

264

265 **Statements**

266 **Acknowledgements**

267 The authors greatly appreciate all the hospital staff for their efforts in recruiting and
268 treating patients and thank all patients involved in this study.

269

270 **Statement of Ethics**

271 The study protocol and waiver of written informed consent were approved by the
272 Medical Ethics Committee of Tongji Hospital Affiliated to Tongji Medical College,
273 Huazhong University of Science and Technology (No. TJ-C20200333).

274

275 **Disclosures Statement**

276 The authors declare that they have no competing interests.

277

278 **Funding Sources**

279 This study was funded by the National Natural Science Foundation of China (NSFC
280 81974089), international (regional) cooperation and exchange projects (NSFC-DFG,
281 Grant No. 81761138041), the Major Research Plan of the National Natural Science
282 Foundation of China (Grant No. 91742204), and the Science Foundation of Hubei
283 Province (2019CFB675).

284

285 **Author Contributions**

286 F.H., G.X., S.G. and Y.Y. conceived and designed the study. Y.N., J.L, Q.L., S.G., and F.H.
287 were in charge of management of patients. Y.Y., J.S., X.X., Y.W., A.C., and F.H. screened,
288 reviewed and recorded the data. Y.Y., J.S. and S.G. performed statistical analyses. Y.Y., J.S.

289 and S.G. drafted the manuscript. All authors provided critical revisions to the manuscript
290 text. All authors read the manuscript and approved the final version.

291

292 **References**

293 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients
294 with Pneumonia in China, 2019. *The New England journal of medicine*. 2020;382(8):727-33.

295 2. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill
296 patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
297 observational study. *Lancet Respir Med*. 2020, Epub ahead of print.

298 DOI:10.1016/S2213-2600(20)30079-5.

299 3. Zarbock A, Gomez H, Kellum JA. Sepsis-induced acute kidney injury revisited:
300 pathophysiology, prevention and future therapies. *Current opinion in critical care*.
301 2014;20(6):588-95.

302 4. Vincent JL. Fluid management in the critically ill. *Kidney international*. 2019;96(1):52-7.

303 5. Xie J, Wang H, Kang Y, Zhou L, Liu Z, Qin B, et al. The Epidemiology of Sepsis in
304 Chinese ICUs: A National Cross-Sectional Survey. *Crit Care Med*. 2020;48(3):e209-e18.

305 6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
306 with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*. 2020, Epub ahead
307 of print. DOI:10.1016/s0140-6736(20)30183-5.

308 7. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in
309 patients with COVID-19 in Wuhan, China. *Clin Infect Dis*. 2020, Epub ahead of print.
310 DOI:10.1093/cid/ciaa248.

311 8. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to

-
- 312 COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care*
- 313 *Med.* 2020, Epub ahead of print. DOI:10.1007/s00134-020-05991-x.
- 314 9. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical Characteristics of
- 315 Coronavirus Disease 2019 in China. *New Engl J Med.* 2020, Epub ahead of print.
- 316 DOI:10.1056/NEJMoa2002032.
- 317 10. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory
- 318 cytokines and chemokines in severe acute respiratory syndrome. *Clin Exp Immunol.*
- 319 2004;136(1):95-103.
- 320 11. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection
- 321 in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. *Cytokine.*
- 322 2018;104:8-13.
- 323 12. Forni LG, Joannidis M. IDEAL timing of renal replacement therapy in critical care. *Nat Rev*
- 324 *Nephrol.* 2019;15(1):5-6.
- 325 13. Wolf T, Kann G, Becker S, Stephan C, Brodt HR, de Leuw P, et al. Severe Ebola virus
- 326 disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care.
- 327 *Lancet (London, England).* 2015;385(9976):1428-35.
- 328 14. Rewa OG, Villeneuve PM, Lachance P, Eurich DT, Stelfox HT, Gibney RTN, et al. Quality
- 329 indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a
- 330 systematic review. *Intensive Care Med.* 2017;43(6):750-63.
- 331 15. Alfaraj SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi AA, Memish ZA. Clinical
- 332 predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
- 333 infection: A cohort study. *Travel Med Infect Dis.* 2019;29:48-50.

-
- 334 16. Karkar A, Ronco C. Prescription of CRRT: a pathway to optimize therapy. *Ann Intensive*
335 *Care*. 2020;10(1):32.
- 336 17. Miao H, Shi J, Wang C, Lu G, Zhu X, Wang Y, et al. Continuous Renal Replacement
337 Therapy in Pediatric Severe Sepsis: A Propensity Score-Matched Prospective Multicenter
338 Cohort Study in the PICU. *Crit Care Med*. 2019;47(10):e806-e13.
- 339 18. Putzu A, Fang MX, Boscolo Berto M, Belletti A, Cabrini L, Cassina T, et al. Blood
340 purification with continuous veno-venous hemofiltration in patients with sepsis or ARDS: a
341 systematic review and meta-analysis. *Minerva Anesthesiol*. 2017;83(8):867-77.
- 342 19. Fayad AI, Buamscha DG, Ciapponi A. Timing of renal replacement therapy initiation for
343 acute kidney injury. *Cochrane Database Syst Rev*. 2018;12:CD010612.
- 344 20. Fayad AI, Buamscha DG, Ciapponi A. Intensity of continuous renal replacement therapy
345 for acute kidney injury. *Cochrane Database Syst Rev*. 2016;10:CD010613.
- 346 21. Allegretti AS, Endres P, Parris T, Zhao S, May M, Sylvia-Reardon M, et al. Accelerated
347 Venovenous Hemofiltration as a Transitional Renal Replacement Therapy in the Intensive
348 Care Unit. *Am J Nephrol*. 2020;51(4):318-26.
- 349 22. Sethi SK, Mittal A, Nair N, Bagga A, Iyenger A, Ali U, et al. Pediatric Continuous Renal
350 Replacement Therapy (PCRRT) expert committee recommendation on prescribing prolonged
351 intermittent renal replacement therapy (PIRRT) in critically ill children. *Hemodial Int*. 2020,
352 Epub ahead of print. DOI:10.1111/hdi.12821.
- 353 23. China. NHC: the New Coronavirus Pneumonia Prevention and Control Program (5th
354 edition) 4 February 2020.
- 355 24. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract*.

-
- 356 2012;120(4):c179-84.
- 357 25. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease
358 pathogenesis. *Semin Immunopathol.* 2017;39(5):517-28.
- 359 26. Giamarellos-Bourboulis EJ. Failure of treatments based on the cytokine storm theory of
360 sepsis: time for a novel approach. *Immunotherapy.* 2013;5(3):207-9.
- 361 27. Chen S, Liu G, Chen J, Hu A, Zhang L, Sun W, et al. Ponatinib Protects Mice From Lethal
362 Influenza Infection by Suppressing Cytokine Storm. *Front Immunol.* 2019;10:1393.
- 363 28. Kennedy JR. Phosphatidylserine's role in Ebola's inflammatory cytokine storm and
364 hemorrhagic consumptive coagulopathy and the therapeutic potential of annexin V. *Med
365 Hypotheses.* 2020;135:109462.
- 366 29. Lau SKP, Lau CCY, Chan KH, Li CPY, Chen H, Jin DY, et al. Delayed induction of
367 proinflammatory cytokines and suppression of innate antiviral response by the novel Middle
368 East respiratory syndrome coronavirus: implications for pathogenesis and treatment. *J Gen
369 Virol.* 2013;94(Pt 12):2679-90.
- 370 30. Li Y, Chen M, Cao H, Zhu Y, Zheng J, Zhou H. Extraordinary GU-rich single-strand RNA
371 identified from SARS coronavirus contributes an excessive innate immune response. *Microbes
372 and infection.* 2013;15(2):88-95.
- 373 31. Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus
374 2019) - recent trends. *Eur Rev Med Pharmacol Sci.* 2020;24(4):2006-11.
- 375 32. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al.
376 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically
377 Proven Protease Inhibitor. *Cell.* 2020, Epub ahead of print. DOI:10.1016/j.cell.2020.02.052.

-
- 378 33. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of
379 ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding
380 SARS pathogenesis. *J Pathol.* 2004;203(2):631-7.
- 381 34. Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, et al.
382 The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on
383 Angiotensin-(1-7). *Physiological reviews.* 2018;98(1):505-53.
- 384 35. Sun ML, Yang JM, Sun YP, Su GH. [Inhibitors of RAS Might Be a Good Choice for the
385 Therapy of COVID-19 Pneumonia]. *Zhonghua Jie He He Hu Xi Za Zhi.* 2020;43(0):E014.
- 386 36. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? *Microbes Infect.* 2020,
387 Epub ahead of print. DOI:10.1016/j.micinf.2020.02.006.
- 388 37. Bar-Or D, Carrick MM, Mains CW, Rael LT, Slone D, Brody EN. Sepsis, oxidative stress,
389 and hypoxia: Are there clues to better treatment? *Redox Rep.* 2015;20(5):193-7.
- 390 38. Chakraborty RK, Burns B. Systemic Inflammatory Response Syndrome. *StatPearls.*
391 *Treasure Island (FL)2020.PMID: 31613449.*
- 392 39. Joannidis M, Forni LG. Clinical review: timing of renal replacement therapy. *Crit Care.*
393 2011;15(3):223.
- 394 40. Matsuda K, Moriguchi T, Oda S, Hirasawa H. Efficacy of continuous hemodiafiltration with
395 a cytokine-adsorbing hemofilter in the treatment of acute respiratory distress syndrome.
396 *Contrib Nephrol.* 2010;166:83-92.
- 397 41. Elbahlawan L, West NK, Avent Y, Cheng C, Liu W, Barfield RC, et al. Impact of
398 continuous renal replacement therapy on oxygenation in children with acute lung injury after
399 allogeneic hematopoietic stem cell transplantation. *Pediatr Blood Cancer.* 2010;55(3):540-5.

-
- 400 42. Han F, Sun R, Ni Y, Hu X, Chen X, Jiang L, et al. Early initiation of continuous renal
401 replacement therapy improves clinical outcomes in patients with acute respiratory distress
402 syndrome. *Am J Med Sci.* 2015;349(3):199-205.
- 403 43. DiCarlo JV, Alexander SR, Agarwal R, Schiffman JD. Continuous veno-venous
404 hemofiltration may improve survival from acute respiratory distress syndrome after bone
405 marrow transplantation or chemotherapy. *J Pediatr Hematol Oncol.* 2003;25(10):801-5.
- 406 44. Edrees F, Li T, Vijayan A. Prolonged Intermittent Renal Replacement Therapy. *Adv*
407 *Chronic Kidney Dis.* 2016;23(3):195-202.
- 408 45. Fathima N, Kashif T, Janapala RN, Jayaraj JS, Qaseem A. Single-best Choice Between
409 Intermittent Versus Continuous Renal Replacement Therapy: A Review. *Cureus.*
410 2019;11(9):e5558.
- 411 46. Ha SO, Kim HS, Park S, Jung KS, Jang SH, Han SJ, et al. Severe ARDS caused by
412 adenovirus: early initiation of ECMO plus continuous renal replacement therapy. *Springerplus.*
413 2016;5(1):1909.
- 414 47. Cha RH, Joh JS, Jeong I, Lee JY, Shin HS, Kim G, et al. Renal Complications and Their
415 Prognosis in Korean Patients with Middle East Respiratory Syndrome-Coronavirus from the
416 Central MERS-CoV Designated Hospital. *J Korean Med Sci.* 2015;30(12):1807-14.
- 417 48. Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, et al. Clinical course and outcomes of critically
418 ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
419 observational study. *The Lancet Respiratory Medicine.* 2020, Epub ahead of print.
420 DOI:10.1016/s2213-2600(20)30079-5.
- 421

Figure Legends

Fig. 1. Kaplan-Meier curve of overall patient survival according to with or without PIRRT treatment. Patient survival was significantly better for PIRRT group than for non-PIRRT group (log-rank test, $P=0.042$).

Table 1. Comparison of baseline demographics and clinical characteristics of COVID-19 patients undergoing invasive mechanical ventilation between patients with and without PIRRT treatment in the cohort

Parameters	All patients	PIRRT group	Non-PIRRT group	P
N	36	22	14	-
Age				0.167 ^a
Mean, years	69.4	67.5	72.6	
SD	10.8	11.4	9.1	
Range, years	44.0-86.0	44.0-86.0	58.0-86.0	
Sex				0.658 ^c
Male, n (%)	30 (83.3)	19 (86.4)	11 (78.6)	
Female, n (%)	6 (16.7)	3 (13.6)	3 (21.4)	
APACHE-II score, mean (SD)	13.7 (4.7)	13.4 (5.4)	14.1 (3.4)	0.633 ^a
SOFA score, median (IQR)	6.0 (4.0-8.0)	6.0 (3.8-8.0)	6.0 (4.5-7.0)	0.994 ^a
Hospitalization, median (IQR), days	6.0 (4.0-9.0)	5.5 (2.8-8.0)	7.5 (4.0-10.0)	0.171 ^a
Comorbidities				
Hypertension, n (%)	14 (38.9)	8 (36.4)	6 (42.9)	0.738 ^c
Diabetes, n (%)	10 (27.8)	6 (27.3)	4 (28.6)	1.000 ^c
Cardiac disease, n (%)	12 (33.3)	6 (27.3)	6 (42.9)	0.472 ^c
Cerebrovascular disease, n (%)	2 (5.6)	0 (0)	2 (14.3)	0.144 ^c
Chronic lung disease, n (%)	7 (19.4)	4 (18.2)	3 (21.4)	1.000 ^c
Malignant tumor, n (%)	2 (5.6)	2 (9.1)	0 (0)	0.511 ^c
Chronic viral hepatitis, n (%)	3 (8.3)	3 (13.6)	0 (0)	0.267 ^c
Any of comorbidity, n (%)	30 (83.3)	18 (81.8)	12 (85.7)	0.759 ^c
Complications				
MODS, n (%)	13 (36.1)	10 (45.5)	3 (21.4)	0.175 ^c
Heart failure, n (%)	7 (19.4)	5 (22.7)	2 (14.3)	0.681 ^c

Acute kidney injury, n (%)	8 (22.2)	5 (22.7)	3 (21.4)	1.000 ^c
Arrhythmia, n (%)	12 (33.3)	8 (36.4)	4 (28.6)	0.727 ^c
ARDS, n (%)	36 (100)	22 (100)	14 (100)	1.000 ^c
Laboratory findings				
White blood cell count, mean (SD), 10 ⁹ /L	14.0 (7.1)	14.3 (8.5)	13.4 (4.4)	0.700 ^a
Neutrophil count, mean (SD), 10 ⁹ /L	12.7 (6.7)	13.0 (8.0)	12.2 (4.2)	0.731 ^a
Lymphocyte count, mean (SD), 10 ⁹ /L	0.6 (0.3)	0.6 (0.3)	0.6 (0.3)	0.546 ^a
Hemoglobin, mean (SD), g/L	122.4 (18.1)	126.8 (18.6)	115.5 (15.5)	0.066 ^a
Platelet, median (IQR), 10 ⁹ /L	156.0 (99.8-213.0)	159.0 (94.0-203.0)	156.0 (110.3-221.5)	0.580 ^b
Blood glucose, mean (SD), mmol/L	9.8 (3.8)	9.0 (2.8)	11.0 (4.8)	0.131 ^a
Total cholesterol, mean (SD), mmol/L	3.3 (0.9)	3.3 (1.0)	3.2 (0.8)	0.669 ^a
hCRP, mean (SD), mg/L	121.0 (76.1)	124.7 (77.0)	105.8 (80.9)	0.667 ^a
Procalcitonin, median (IQR), ng/mL	0.32 (0.19-0.83)	0.3 (0.2-1.0)	0.3 (0.3-0.9)	0.538 ^b
Ferritin, median (IQR), µg/L	1140.0 (799.0-1983.0)	1264.0 (795.4-2108.0)	1077.0 (806.4-1933.0)	0.637 ^b
Prothrombin time, median (IQR), s	15.5 (14.5-16.3)	15.1 (14.1-16.3)	15.7 (14.9-16.6)	0.299 ^b
Activated partial thromboplastin time, median (IQR), s	38.7 (36.0-44.7)	38.7 (35.4-43.7)	39.0 (37.0-51.9)	0.158 ^b
hs-cTnI, median (IQR), pg/mL	67.7 (16.0-284.9)	79.3 (16.3-587.2)	46.3 (14.6-162.0)	0.337 ^b
NT-proBNP, median (IQR), µg/mL	1.2 (0.6-3.0)	1.1 (0.6-2.8)	1.2 (0.5-3.6)	0.781 ^b
Alanine aminotransferase, median (IQR), U/L	34.5 (21.5-45.5)	36.0 (29.0-53.0)	30.5 (16.0-43.3)	0.081 ^b
Aspartate aminotransferase, median (IQR), U/L	30.5 (22.5-54.0)	43.5 (24.0-63.3)	29.5 (20.0-34.0)	0.034 ^{b*}
Blood urea nitrogen, median (IQR), mmol/L	10.7 (6.7-14.4)	10.8 (6.4-14.9)	10.3 (6.9-13.6)	0.923 ^b
Serum creatinine, median (IQR), µmol/L	83.5 (66.0-126.3)	94.5 (67.0-136.0)	72.0 (51.0-82.3)	0.017 ^{b*}
Serum bicarbonate, mean (SD), mmol/L	24.7 (3.4)	24.3 (2.9)	25.4 (4.1)	0.345 ^a
Potassium, median (IQR), mmol/L	4.1 (3.5-4.6)	4.1 (3.5-4.8)	4.2 (3.6-4.6)	0.968 ^b
Lactic acid, median (IQR), mmol/L	2.3 (1.8-2.9)	2.4 (1.9-2.8)	2.3 (1.8-3.0)	0.811 ^b

Treatments

Moxifloxacin hydrochloride, n (%)	24 (66.7)	16 (72.7)	8 (57.1)	0.472 ^c
Abidol, n (%)	28 (77.8)	17 (77.3)	11 (78.6)	1.000 ^c
Lopinavir/ritonavir, n (%)	10 (27.8)	8 (36.4)	2 (14.3)	0.255 ^c
Hydroxychloroquine, n (%)	3 (8.3)	2 (9.1)	1 (7.1)	1.000 ^c
Other antibiotic treatment, n (%)	34 (94.4)	21 (95.5)	13 (92.9)	1.000 ^c
Antifungal treatment, n (%)	5 (13.9)	5 (22.7)	0 (0)	0.134 ^c
Other antiviral treatment, n (%)	4 (11.1)	1 (4.5)	3 (21.4)	0.134 ^c
Traditional Chinese medicine, n (%)	20 (55.6)	12 (54.5)	8 (57.1)	1.000 ^c
Glucocorticoid, n (%)	29 (80.6)	17 (77.3)	12 (85.7)	0.681 ^c
Diuretics, n (%)	27 (75.0)	15 (68.2)	12 (85.7)	0.432 ^c
Human albumin, n (%)	34 (94.4)	21 (95.5)	13 (92.9)	1.000 ^c
Gamma globulin, n (%)	29 (80.6)	18 (81.8)	11 (78.6)	1.000 ^c
Heparin, n (%)	29 (80.6)	17 (77.3)	12 (85.7)	0.681 ^c
IABP, n (%)	2 (5.6)	1 (4.5)	1 (7.1)	1.000 ^c
ECMO, n (%)	3 (8.3)	3 (13.6)	0 (0)	0.267 ^c
Duration of invasive mechanical ventilation to initiation of PIRRT, median (IQR), days	-	3.5 (2.0-6.3)	-	-

*P<0.05. ^at-test, ^bWhitney U test, ^cFisher's exact test.

COVID-19, coronavirus disease 2019; APACHE II, acute physiology and chronic health evaluation II; SOFA, sepsis-related organ failure assessment; PIRRT, prolonged intermittent renal replacement therapy; MODS, multiple organ dysfunction syndrome; IABP, intra aortic balloon counterpulsation; SD, standard deviation; IQR, interquartile range; ARDS, acute respiratory distress syndrome; hCRP, hypersensitive C-reactive protein; hs-cTnI, high sensitive cardiac troponin I; NT-proBNP, N-terminal pro-brain natriuretic peptide; ECMO, extracorporeal membrane oxygenation.

Table 2. Models of multivariate Cox proportional hazard regression analysis for PIRRT treatment (reference group: non-PIRRT treatment) for all-cause mortality of all COVID-19 patients undergoing invasive mechanical ventilation in the cohort


PIRRT versus non-PIRRT	Adjusted Hazard Ratio (95% CI)	P
Model A	0.350 (0.147, 0.830)	0.017
Model B	0.398 (0.171, 0.924)	0.032
Model C	0.332 (0.119, 0.925)	0.035

Model A: Adjusted for APACHE II scores, SOFA scores, and any of comorbidity;
Model B: Adjusted for Acute kidney injury, APACHE II scores, Sex;
Model C: Adjusted for IL-6, APACHE II scores, IL-2 receptor.

Table 3. Univariate Cox proportional hazard regression analysis for all-cause mortality of COVID-19 patients undergoing invasive mechanical ventilation with PIRRT treatment in the cohort

Parameters	Hazard Ratio (95% CI)	P
Age (per year)	1.048 (0.998, 1.100)	0.059
Sex (male vs. female)	0.959 (0.209, 4.397)	0.957
APACHE II score (per 1 score)	1.038 (0.942, 1.143)	0.453
SOFA score (per 1 score)	1.093 (0.948, 1.261)	0.221
Any of comorbidity (with vs. without)	1.720 (0.379, 7.816)	0.483
Acute kidney injury (with vs. without)	2.219 (0.674, 7.313)	0.190
White blood cell count (per 10 ⁹ /L)	0.980 (0.918, 1.047)	0.553
IL-2 receptor (per U/mL)	1.002 (1.001, 1.003)	0.004*
TNF- α (per pg/mL)	1.046 (1.002, 1.092)	0.041*
Procalcitonin (per ng/L)	2.306 (1.098, 4.842)	0.027*
Prothrombin time (per s)	1.808 (1.229, 2.659)	0.003*
D-dimer (per μ g/mL [FEU])	1.034 (0.964, 1.109)	0.346
hs-cTnI (per pg/mL)	1.000 (1.000, 1.000)	0.257
NT-proBNP (per μ g/mL)	1.181 (1.056, 1.320)	0.003*
Alanine aminotransferase (per U/L)	0.998 (0.992, 1.004)	0.479
Aspartate aminotransferase (per U/L)	0.998 (0.994, 1.003)	0.442
Plasma albumin (per g/L)	1.010 (0.856, 1.191)	0.910
Blood urea nitrogen (per mmol/L)	1.021 (0.950, 1.099)	0.569
Serum creatinine (per μ mol/L)	1.000 (0.987, 1.012)	0.963

COVID-19, coronavirus disease 2019; PIRRT, prolonged intermittent renal replacement therapy; APACHE II, acute physiology and chronic health evaluation II; SOFA, sepsis-related organ failure assessment; IL, interleukin; TNF, tumor necrosis factor; FEU, fibrinogen equivalent units; hs-cTnI, high sensitive cardiac troponin I; NT-proBNP, N-terminal pro-brain natriuretic peptide.



Number at risk		Time (days)					
	0	7	14	21	28	35	
PIRRT group	22	17	12	10	9	4	
non-PIRRT group	14	6	3	3	3	2	